profile identified that predicts risk of infection in multiple myeloma
The results of this study by Cima de Navarra will enable more personalized medicine that identifies the most vulnerable patients at an early stage.
PhotoManuel research group research group Multiple Myeloma group at Cima participated in the study.
25 | 02 | 2026
Multiple myeloma is a blood cancer that occurs in the bone marrow. It is caused by the proliferation of plasma cells, a subject immune cell responsible for producing antibodies. One of the main complications of this disease and a frequent cause of hospitalization is infection. However, knowledge about immune dysfunction and its association infection is limited. Until now, it has not been possible to accurately identify the profile of patients at highest risk.
An international study led by researchers from Cima de Navarra and the group Myeloma group (GEM/PETHEMA) has analyzed the profile of 1,800 patients in different stages of multiple myeloma in order to identify specific immune system alterations associated with an increased risk of infection. The researchers developed an immunological score capable of stratifying patients according to their likelihood of suffering infections.
Patients with two or more disorders
"This work, carried out at the Cancer Center Clínica Universidad de Navarra, has identified that patients with two or more immunological alterations in B, T, and NK lymphocytes presented a significantly higher risk," says Dr. Bruno Paiva, researcher of the Multiple Myelomagroup . In addition, according to the Cima scientist, "the markers identified were validated in three international cohorts and can be measured using techniques available in standard clinical laboratories, which facilitates their possible incorporation into internship ." The findings have been published in the latest issue the scientific journalBlood.
These results open the door to a new, more personalized medicine, allowing for the early identification of the most vulnerable patients and strengthening infection prevention strategies for them with the goal improving their safety and quality of life.
The study was conducted within the framework CIBER Cancer Network (CIBERONC) and was funded by committee research committee research the Carlos III Health Institute, with support from private institutions such as the association Against Cancer, the CRIS Cancer Foundation, the International Myeloma Society, and the Riney Family Foundation.
reference letter
Blood Jan 26. doi: 10.1182/blood.2025031744.
Immune biomarkers of increased infection risk in multiple myeloma